GLP-1RAs were associated with an increased risk of GERD and cholelithiasis but did not significantly increase the risk of pancreatitis, cholecystitis, intestinal obstruction, or other serious gastrointestinal or biliary events. GLP-1 RAs were associated with increased the risk

Summary of REDEFINE 1 and REDEFINE 2 trials with CagriSema, presented this week at #ADA2025 and published in NEJM: REDEFINE 1: • 👥 3,417 participants with obesity or overweight (without diabetes) treated with CagriSema achieved a 22.7% weight loss after 68 weeks, compared to

🧠 Tirzepatide doesn’t just reduce appetite—it rewires the brain. - - - A new Nature Medicine Phase 1 RCT (n=114) explored how tirzepatide changes eating behavior—and the brain’s response to food—in people with overweight or obesity. 📉 Key Findings at 3–6 Weeks 🔹-524 kcal/day

✨أرقام عن أمراض السكري في السعودية🇸🇦 🔺نسبة انتشار أمراض السكري في السعودية تقدر بـ ٢٣.١٪ اي ٤.٦٢ ميلون مصاب. 🔺٢-٣ من كل ١٠ أشخاص بالغين بالسعودية مصابين بالسكري. المصدر: الاتحاد الدولي للسكري ٢٠٢٥

While obesity is generally related to polygenic + environmental factors, rare monogenic forms (e.g., leptin-melanocortin defects) expose fundamental metabolic control points 🧬 #PrecisionMedicine #obesity

Statistically significant & clinically meaningful reductions in LDL-C in both Phase 3 CORALreef HeFH and CORALreef AddOn trials This could be potentially the first approved oral #PCSK9 #Hyperlipidemia #LDL

In patients with compensated cirrhosis from metabolic dysfunction–associated steatohepatitis, efruxifermin did not significantly reduce fibrosis at 36 weeks. Full SYMMETRY trial results and Research Summary: nej.md/4kru98f

Yet another GLP-1 agonist completes a phase 3 trial in adults with overweight or obesity. 🧪⚖️ Ecnoglutide, a subcutaneous once weekly injection, generated 13.2% weight loss in the highest dose vs 0.1% in placebo. 💉📉 Adverse events were comparable to the rest of the class of

🚨دواء تم الموافقة عليه في الصين لإنقاص الوزن أول دواء في العالم يدمج هرمونين GLP1 + Glucagon receptor agonist لعلاج #السمنة ابرة أسبوعية بجرعتين مختلفين 🚀نتائج مذهلة: خسارة ممكن تصل إلى ١٤.٨٪ من الوزن في ٤٨ اسبوع From phase 3 GLORY-1 study nejm.org/doi/full/10.10…

Poorly Differentiated Neuroendocrine Carcinomas - by Garcia-Carbonero's Lab at ESMO - Eur. Oncology #ESMOGI25 👉Poorly dif 👉High Ki67 👉Agressive 🏥Chemo ASAP (PlatinumEtoposide) ✅FDG-PET (⛔️SSTR; 28% would to a Ga-PET 😫) 🤞🏻IO promising #ESMOAmbassadors Rachel Riechelmann Juan OConnor

Why Do Patients Discontinue GLP-1 Medications for Obesity? Adherence Challenges ❌ 50% stop treatment within 6 months Top Reasons for Stopping 🤢 Side effects (mainly GI): 36% 🚗 Logistics (travel, time): 24% 💰 Cost & affordability: 23% dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

What type of hyperparathyroidism do I have? If your calcium is normal but PTH elevated, it might not be *primary* hyperparathyroidism—it could be *secondary*. 🧪 Common causes include: 🔹 Chronic kidney disease 🔹 Vitamin D deficiency 🔹 Certain medications #PAM2025

"وما ينبغي للشمس أن تغيب إلا بإذن ربها"

🧬 #Gene therapy is entering #lipidology 💡 From #HoFH to Lp(a), CRISPR & mRNA tools target lifelong lipid control A new European Society of Cardiology review summarizes mechanisms, early trials & challenges 📄 Eur Heart J 2025 🔗 doi.org/10.1093/eurhea… #EndoTwitter #GeneTherapy #CVPrevention

مشاركة متميزة وظهور مشرّف لممثل الوطن فريق "الهلال" في منافسات كأس العالم للأندية 🇸🇦 شكرًا للاعبين والجهاز الفني والإداري على الأداء الرائع 👏🏼 وكل الأمنيات دائماً للفرق السعودية بتقديم مستويات مميزة في المحافل العالمية،لتأكيد تطور كرة القدم في وطننا الغالي.

“If you treat someone’s blood pressure or cholesterol you don’t get improvements in quality of life. You treat their weight you get all the benefits." "That is the power of treating obesity.” Inspiring talk by Dr. Lou Aronne on the clinical implications of CagriSema at

#Obesity medication expected to be approved to use in the next few years Other than obesity, the upcoming research areas also focus on heart failure, kidney disease, #MASH, and even CNS disorders such as Alzheimer’s and Parkinson’s. Next 5-10 Years Looks exciting & bright 😍👏🏻

Meta-analysis of GLP-1RAs and gastrointestinal adverse events. GLP-1RAs are associated with an increased risk of cholelithiasis and GERD, but do not appear to increase the risk of other gastrointestinal or biliary adverse events. gastrojournal.org/article/S0016-…